Incyte Valuation
Is INCY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Earnings vs. similares
Price-To-Earnings vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of INCY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: INCY ($62.28) cotiza por debajo de nuestra estimación de valor razonable ($231.17)
Muy por debajo del valor justo: INCY cotiza por debajo de su valor razonable en más de un 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INCY?
Other financial metrics that can be useful for relative valuation.
| What is INCY's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$12.35b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.4x |
| Enterprise Value/EBITDA | 11.8x |
| PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does INCY's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 46.3x | ||
UTHR United Therapeutics | 11.2x | 7.6% | US$10.9b |
BMRN BioMarin Pharmaceutical | 97.8x | 30.4% | US$16.4b |
NBIX Neurocrine Biosciences | 54.8x | 26.5% | US$13.7b |
BNTX BioNTech | 21.2x | -20.6% | US$21.6b |
INCY Incyte | 20.7x | 20.1% | US$12.3b |
Price-To-Earnings vs. similares: INCY es un buen valor basado en su Ratio Price-To-Earnings (32.8x) comparado con la media de sus homólogos (69.2x).
Price to Earnings Ratio vs Industry
How does INCY's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs. Industria: INCY es un buen valor basado en su Ratio Price-To-Earnings (21.4x) comparado con la media del sector US Biotechs (21.6x).
Price to Earnings Ratio vs Fair Ratio
What is INCY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 20.7x |
| Fair PE Ratio | 28.3x |
PM vs. Ratio Justo: INCY es un buen valor basado en su Ratio Price-To-Earnings (22.3x) comparado con el Ratio estimado Fair Price-To-Earnings (28.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$54.99 | US$76.01 +38.2% | 14.1% | US$92.00 | US$58.00 | n/a | 21 |
| Mar ’25 | US$59.05 | US$75.82 +28.4% | 13.6% | US$92.00 | US$58.00 | n/a | 21 |
| Feb ’25 | US$59.16 | US$77.05 +30.2% | 15.7% | US$93.00 | US$58.00 | n/a | 21 |
| Jan ’25 | US$62.79 | US$77.10 +22.8% | 15.6% | US$93.00 | US$58.00 | n/a | 21 |
| Dec ’24 | US$54.02 | US$76.16 +41.0% | 16.5% | US$93.00 | US$58.00 | n/a | 20 |
| Nov ’24 | US$54.37 | US$77.91 +43.3% | 16.5% | US$98.00 | US$58.00 | n/a | 20 |
| Oct ’24 | US$57.77 | US$83.59 +44.7% | 13.3% | US$114.00 | US$65.00 | n/a | 19 |
| Sep ’24 | US$64.69 | US$83.59 +29.2% | 13.3% | US$114.00 | US$65.00 | n/a | 19 |
| Aug ’24 | US$63.69 | US$83.31 +30.8% | 13.4% | US$114.00 | US$65.00 | n/a | 19 |
| Jul ’24 | US$62.25 | US$83.11 +33.5% | 14.6% | US$109.00 | US$60.00 | n/a | 18 |
| Jun ’24 | US$61.51 | US$82.42 +34.0% | 14.8% | US$109.00 | US$60.00 | n/a | 19 |
| May ’24 | US$75.34 | US$89.10 +18.3% | 15.5% | US$119.00 | US$61.00 | n/a | 19 |
| Apr ’24 | US$72.27 | US$88.67 +22.7% | 15.8% | US$118.00 | US$61.00 | US$56.64 | 18 |
| Mar ’24 | US$77.83 | US$88.89 +14.2% | 15.6% | US$118.00 | US$63.00 | US$59.05 | 18 |
| Feb ’24 | US$85.60 | US$89.11 +4.1% | 16.2% | US$120.00 | US$63.00 | US$59.16 | 18 |
| Jan ’24 | US$80.32 | US$88.06 +9.6% | 17.2% | US$123.00 | US$63.00 | US$62.79 | 17 |
| Dec ’23 | US$80.68 | US$87.94 +9.0% | 17.2% | US$123.00 | US$63.00 | US$54.02 | 17 |
| Nov ’23 | US$76.95 | US$87.65 +13.9% | 16.7% | US$119.00 | US$63.00 | US$54.37 | 17 |
| Oct ’23 | US$66.64 | US$88.47 +32.8% | 16.6% | US$119.00 | US$63.00 | US$57.77 | 17 |
| Sep ’23 | US$71.35 | US$88.71 +24.3% | 16.4% | US$119.00 | US$63.00 | US$64.69 | 17 |
| Aug ’23 | US$77.40 | US$92.28 +19.2% | 16.2% | US$127.00 | US$63.00 | US$63.69 | 18 |
| Jul ’23 | US$77.67 | US$92.31 +18.9% | 16.6% | US$124.00 | US$58.00 | US$62.25 | 16 |
| Jun ’23 | US$74.98 | US$92.44 +23.3% | 16.5% | US$124.00 | US$58.00 | US$61.51 | 16 |
| May ’23 | US$74.96 | US$92.07 +22.8% | 17.5% | US$125.00 | US$56.00 | US$75.34 | 15 |
| Apr ’23 | US$79.94 | US$91.13 +14.0% | 18.5% | US$125.00 | US$56.00 | US$72.27 | 15 |
Pronóstico de los analistas: El precio objetivo es más de un 20% superior al precio actual de la acción y los analistas están dentro de un rango de acuerdo estadísticamente seguro.